USFDA completes inspection of Lupin’s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations”.

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.

  • Related Posts

    • Pharma
    • June 10, 2025
    • 74 views
    Eye stroke alert: Ozempic linked to rare vision-loss condition

    If you’re on Ozempic or Wegovy to manage type 2 diabetes—or to shed some pounds—there’s something new you should have on your radar. Doctors are now flagging a rare but…

    • Pharma
    • June 10, 2025
    • 70 views
    Glenmark to launch cancer drug Zanubrutinib in India

    New Delhi:  Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Eye stroke alert: Ozempic linked to rare vision-loss condition

    Eye stroke alert: Ozempic linked to rare vision-loss condition

    Glenmark to launch cancer drug Zanubrutinib in India

    Glenmark to launch cancer drug Zanubrutinib in India

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million